The share of the Indian market in the overall turnover of pharmaceutical (pharma) companies has risen in the past few years. There are several reasons behind this: pricing pressure in the US generics market, currency volatility in the emerging markets (EMs), and India being the only consistent geography with stable prices and demand.
A Business Standard analysis reveals how the share of the India business in the overall turnover rose steadily from 25 per cent in 2018-19 (FY19) for Sun Pharmaceutical Industries (Sun Pharma) to 33 per cent in 2021-22 (FY22). The company ranks No. 1 in the Indian market,